Peripheral vascular

See clearly.

Treat optimally.

Datele de contact

* Acest câmp este obligatoriu
*
*
*
*
*
*
*
*
*
Înapoi
Specifică-ne motivul pentru care doreşti să ne contactezi pentru a-ţi putea fi cât mai de folos
*
*
Înapoi
Angio alone image

Angiography alone is

not enough

Angiography provides information on luminal characteristics of peripheral arteries, but severely underestimates the extent of atherosclerosis in patients with PAD, even in “normal appearing” vessels.1

Visualize the best path forward with IVUS eyes

Philips IVUS provides the visualization needed to gain deeper insights into the lesion and choose the best procedural path forward.
IVUS changed treatment
One icon
Lumen
Two icon
Eccentric fibrotic plaque with deep calcium module
Three icon
Accoustic shadowing

Vessel size

Guides device sizing to ensure precise wall apposition, drug delivery, and placement
Vessel diameter
Vessel diameter
Lumen diameter
Lumen diameter
Plaque burden
Plaque burden

Plaque morphology

Understand plaque type and severity to help guide proper device selection
Soft
Soft
Fibrous
Fibrous
Calcific
Calcific
Thrombus
Thrombus
CTO
CTO

Plaque geometry

Visualize plaque burden location for precise treatment
Concentric
Concentric
Eccentric
Eccentric

Guidewire position

Confirm true lumen or sub-intimal guidewire location
True lumen
True lumen
Sub-intimal
Sub-intimal

Confirm optimal treatment with IVUS

No dissections  •  Reduce residual stenosis  •  Stent fully deployed  •  Treated entire lesion

Treat optimally with versatility

The Philips portfolio of therapeutic devices offers the versatility needed to treat the majority of PAD cases, including complex lesions. 

Crossing

Cross your toughest lesions
Quick-Cross catheter
The support you need to handle any lesion
Pioneer Plus catheter
Only IVUS-guided re-entry catheter

Vessel prep

Prepare multiple lesion morphologies, locations and characteristics
Turbo-Elite and Turbo-Power laser atherectomy
Clinically proven ablation in all lesion types above and below the knee; indicated for ISR2
Phoenix atherectomy system
Front-cutting mechanical atherectomy for treating mixed morphologies with low risk of embolization3
AngioSculpt
Reduces risk of flow limiting dissections including in calcified lesions4

Definitive treatment

Treat lesions without leaving metal behind
Stellarex drug-coated balloon

Durable treatment effect in common to complex patients with a low drug dose 

 

2-year primary patency 75.2% in common patients and 72.1% complex patients, including highest rate of severely calcified lesions5,6

 

No mortality signal in pooled ILLUMENATE RCT analysis and larger data set through 3 years7

Treat safely and effectively

with low-dose Philips Stellarex drug-coated balloon
Angio alone image

Full view treatment planning

 

The integration of visualization and interventional technologies allows physicians to see the complete picture and create a more informed and individualized procedural approach.

Treatment plan example 1
Treatment plan example 2
Treatment plan example 1
Treatment plan example one
One icon
Lumen
Two icon
Eccentric fibrotic plaque with deep calcium nodule
Three icon
Acoustic shadowing
Treatment plan example 2
Treatment plan example two
One icon
Lumen with fresh thrombus
Two icon
Micro-calcification
Three icon
Calcified plaque with acoustic shadowing

See clearly

   

Vessel size: 5.5 mm diameter

Plaque morphology: Fibrotic plaque with intimal and medial calcium

Plaque geometry: Eccentric lesion

Guidewire position: True lumen

   

Vessel size: 6 mm diameter

Plaque morphology: Mixed, thrombic plaque with medial calcium

Plaque geometry: Eccentric lesion

Guidewire position: True lumen

Treat optimally

   

Quick-Cross catheter: Confidently cross challenging morphologies

Phoenix deflecting atherectomy: Front facing to cut, capture and clear mixed morphologies, including calcium; deflecting capabilities for larger luminal gain

AngioSculpt scoring balloon: Score calcium to reduce dissection4

Stellarex DCB: Designed for performance in calcium

   

Quick-Cross catheter: Confidently cross challenging morphologies

Turbo-Power laser atherectomy: Forward facing directional debulking to clear thrombus; rotation for improved deliverability in calcified lesions

AngioSculpt scoring balloon: Safely dilate residual stenosis4

Stellarex DCB: Designed for performance in calcium

1. Kashyap VS. Pavkov ML, Bishop PD, et al. Angiography underestimates peripheral atherosclerosis: lumenography revisited. J Endovasc Ther. 2008;15(1): 117-125.

2. Dippel et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015 Jan;8(1 Pt A):92-101

3. Davis, Thomas et al., Safety and effectiveness of the Phoenix Atherectomy System in lower extremity arteries: Early and midterm outcomes from the prospective multicenter EASE study. Vascular. September 27, 2017, DOI: 10.1177/1708538117712383.  

4. Kiesz RS, Scheinert D, Peeters PJ, et al. Results from the international registry of the AngioSculpt Scoring Balloon Catheter. J Am Coll Cardiol. 2008;51:10(suppl B);75.

5. Brodmann M, Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon The ILLUMENATE European Randomized Clinical Trial 2-Year Results, J Am Coll Cardiol Intv 2018;11:2357–64. Dec 2018

6. Mathews J. NCVH, 2019. Stellarex in the Treatment of the SFA and Popliteal: Late-Breaking 3-Year Data. May 29, 2109 New Orleans, LA.

7. Lyden, S. LINC, 2019. Long-term safety data from the Stellarex DCB program Jan. 22, 2019. Leipzig, Germany.

8. Bard Lutonix Instructions for Use, BAW1387400r3

 

Refer to product labeling for complete indications, contraindications, and warnings.

Caution: federal law restricts this device to sale by or on the order of physician

Some or all products manufactured by Spectranetics, a Philips company. Approved for external distribution. D050123-00 042019

 

*Data from independent CEC (clinical events committee) adjudication of all events resulting in death across all studies.